HSP90AA1 and cancer: Future studies are needed to define whether HSP90 N‐terminal inhibitors in combination with conventional endocrinal therapy drugs or DNA‐damaging chemotherapeutic agents or radiotherapy have synergistic effects on MORC2‐expressing cancers.